Filing Details
- Accession Number:
- 0001209191-19-019524
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-03-14 17:51:07
- Reporting Period:
- 2019-03-12
- Accepted Time:
- 2019-03-14 17:51:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1689813 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1704251 | John Tilton | C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Acquisiton | 2019-03-12 | 10,000 | $9.29 | 10,000 | No | 4 | M | Direct | |
Common Shares | Disposition | 2019-03-12 | 10,000 | $50.11 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Employee Stock Option (Right to Buy) | Disposition | 2019-03-12 | 10,000 | $0.00 | 10,000 | $9.29 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
78,792 | 2027-01-30 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Shares | 1,614 | Indirect | By JET Ventures LLC |
Footnotes
- The exercise and sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 - $50.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The shares underlying this option vested as to 50% of the shares on January 31, 2017, with the remainder vesting in 2 equal installments on the first and second anniversaries of the grant date.